{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:11:04Z","timestamp":1785409864727,"version":"3.56.0"},"posted":{"date-parts":[[2026,6,21]]},"group-title":"Immunology","reference-count":79,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["Scholar Career Development Award"],"award-info":[{"award-number":["Scholar Career Development Award"]}],"id":[{"id":"https:\/\/ror.org\/03h1gea69","id-type":"ROR","asserted-by":"publisher"}]},{"award":["Million Mile Researcher Program"],"award-info":[{"award-number":["Million Mile Researcher Program"]}],"id":[{"id":"https:\/\/ror.org\/038ja4880","id-type":"ROR","asserted-by":"publisher"}]},{"award":["Cancer Research Fund"],"award-info":[{"award-number":["Cancer Research Fund"]}],"id":[{"id":"https:\/\/ror.org\/04537p149","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Giant Food Pediatric Cancer Campaign"},{"award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Immunotherapy approaches have shown limited efficacy in pediatric sarcomas, partly because these tumors have low mutation burden and few neoantigens. We sought to increase the immunogenicity of low mutation sarcomas by inducing expression of epigenetically silenced genes using the hypomethylating agent decitabine and histone deacetylase inhibitor entinostat. Using a mutated Kras-driven murine sarcoma model KP Sarc, sequential treatment with decitabine and entinostat significantly increased expression of silenced genes, including cancer testis antigens, and enhanced antigen presentation, including MHC I expression, compared with either agent alone. Vaccination with irradiated, epigenetically treated KP Sarc cells in a GM-CSF-secreting whole-cell vaccine induced T cell immunity against a matched tumor challenge. The anti-tumor response was directed toward epigenetically upregulated antigens, was T cell dependent, was further potentiated by immune checkpoint inhibition, and conferred immunologic memory. We showed that epigenetically regulated antigens can be shared between tumors providing protective immunity against both epigenetically treated KP Sarc and a second murine sarcoma M-3-9M. Treatment of human sarcoma lines with decitabine and entinostat induced similar gene expression changes, including shared antigen targets, and increased MHC I expression. These findings demonstrate that epigenetically upregulated antigens can serve as effective tumor-specific targets and broaden immunotherapy strategies for low-mutation sarcomas.<\/jats:p>","DOI":"10.64898\/2026.06.18.733244","type":"posted-content","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:40:14Z","timestamp":1782085214000},"source":"Crossref","is-referenced-by-count":0,"title":["Combination epigenetic-targeted therapy increases the immunogenicity of poorly immunogenic sarcomas"],"prefix":"10.64898","author":[{"given":"Alice","family":"Recho","sequence":"first","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himavanth R.","family":"Gatla","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Resch","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"Cellular and Molecular Medicine Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Glavaris","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"Cellular and Molecular Medicine Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Doucet","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.M.","family":"Looi","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Barbato","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-0858","authenticated-orcid":false,"given":"Nicolas J.","family":"Llosa","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-6644","authenticated-orcid":false,"given":"Michael A.","family":"Koldobskiy","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-416X","authenticated-orcid":false,"given":"Brian H.","family":"Ladle","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"Cellular and Molecular Medicine Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026062310301875000_2026.06.18.733244v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.03.007"},{"issue":"1","key":"2026062310301875000_2026.06.18.733244v1.2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","year":"2012","journal-title":"Clinical sarcoma research"},{"key":"2026062310301875000_2026.06.18.733244v1.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-4-348"},{"key":"2026062310301875000_2026.06.18.733244v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"2026062310301875000_2026.06.18.733244v1.5","doi-asserted-by":"crossref","unstructured":"Davis KL , et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. The Lancet Oncology. 2020.","DOI":"10.1016\/S1470-2045(20)30023-1"},{"issue":"23","key":"2026062310301875000_2026.06.18.733244v1.6","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A Phase I\/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed\/Refractory Solid Tumors: A Children\u2019s Oncology Group Study ADVL1412","volume":"28","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026062310301875000_2026.06.18.733244v1.7","doi-asserted-by":"crossref","unstructured":"Hargrave D , et al. Phase I\/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. Front Oncol. 2026;16:1680081.","DOI":"10.3389\/fonc.2026.1680081"},{"key":"2026062310301875000_2026.06.18.733244v1.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0903"},{"key":"2026062310301875000_2026.06.18.733244v1.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2026062310301875000_2026.06.18.733244v1.10","doi-asserted-by":"crossref","unstructured":"Vitale I , et al. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends in cell biology. 2019.","DOI":"10.1016\/j.tcb.2019.01.003"},{"issue":"1","key":"2026062310301875000_2026.06.18.733244v1.11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13073-017-0468-3","article-title":"The neoepitope landscape in pediatric cancers","volume":"9","year":"2017","journal-title":"Genome Medicine"},{"key":"2026062310301875000_2026.06.18.733244v1.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0639"},{"key":"2026062310301875000_2026.06.18.733244v1.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1037"},{"key":"2026062310301875000_2026.06.18.733244v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3416"},{"issue":"5","key":"2026062310301875000_2026.06.18.733244v1.15","doi-asserted-by":"crossref","first-page":"e001772","DOI":"10.1136\/jitc-2020-001772","article-title":"Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes","volume":"9","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2026062310301875000_2026.06.18.733244v1.16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","article-title":"Nucleosidic DNA demethylating epigenetic drugs \u2013 A comprehensive review from discovery to clinic","volume":"188","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"key":"2026062310301875000_2026.06.18.733244v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"2026062310301875000_2026.06.18.733244v1.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1712514114"},{"issue":"41","key":"2026062310301875000_2026.06.18.733244v1.19","doi-asserted-by":"crossref","first-page":"70798","DOI":"10.18632\/oncotarget.19990","article-title":"Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2026062310301875000_2026.06.18.733244v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14889"},{"key":"2026062310301875000_2026.06.18.733244v1.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0070"},{"key":"2026062310301875000_2026.06.18.733244v1.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.771014"},{"key":"2026062310301875000_2026.06.18.733244v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.022"},{"key":"2026062310301875000_2026.06.18.733244v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/5047"},{"issue":"4","key":"2026062310301875000_2026.06.18.733244v1.25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.21037\/tcr.2018.06.24","article-title":"Tumor immunotherapy-the potential of epigenetic drugs to overcome resistance","volume":"7","year":"2018","journal-title":"Translational Cancer Research"},{"key":"2026062310301875000_2026.06.18.733244v1.26","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18803.x"},{"key":"2026062310301875000_2026.06.18.733244v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.04.005"},{"key":"2026062310301875000_2026.06.18.733244v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1731-3"},{"key":"2026062310301875000_2026.06.18.733244v1.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0582-6"},{"key":"2026062310301875000_2026.06.18.733244v1.30","doi-asserted-by":"crossref","unstructured":"Kim VM , et al. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight. 2020;5(9).","DOI":"10.1172\/jci.insight.136368"},{"key":"2026062310301875000_2026.06.18.733244v1.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179501"},{"key":"2026062310301875000_2026.06.18.733244v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029"},{"key":"2026062310301875000_2026.06.18.733244v1.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0741"},{"issue":"6","key":"2026062310301875000_2026.06.18.733244v1.34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","year":"2024","journal-title":"Nat Cancer"},{"key":"2026062310301875000_2026.06.18.733244v1.35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030815"},{"key":"2026062310301875000_2026.06.18.733244v1.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2008.00070.x"},{"key":"2026062310301875000_2026.06.18.733244v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23048"},{"key":"2026062310301875000_2026.06.18.733244v1.38","unstructured":"Laborat\u00f3rio Nacional de Computa\u00e7\u00e3o Cient\u00edfica (LNCC) P, RJ, Brazil, Ludwig Institute for Cancer Research (LICR New York Branch). CTDatabase. http:\/\/www.cta.lncc.br\/index.html. Accessed 5\/15\/2026, 2026."},{"key":"2026062310301875000_2026.06.18.733244v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3198"},{"issue":"8","key":"2026062310301875000_2026.06.18.733244v1.40","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-24-2335","article-title":"LRRC15-CAR T Cells for the Treatment of Osteosarcoma","volume":"32","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026062310301875000_2026.06.18.733244v1.41","doi-asserted-by":"crossref","first-page":"e28771","DOI":"10.1002\/pbc.28771","article-title":"LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies","volume":"68","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026062310301875000_2026.06.18.733244v1.42","doi-asserted-by":"crossref","unstructured":"Ben-Ami E , et al. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel ). 2020;12(3).","DOI":"10.3390\/cancers12030757"},{"key":"2026062310301875000_2026.06.18.733244v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05272-1"},{"key":"2026062310301875000_2026.06.18.733244v1.44","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1957754"},{"key":"2026062310301875000_2026.06.18.733244v1.45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06743-2"},{"key":"2026062310301875000_2026.06.18.733244v1.46","doi-asserted-by":"crossref","unstructured":"Zhao K , et al. INHBA is a Prognostic Biomarker and Correlated With Immune Cell Infiltration in Cervical Cancer. Front Genet. 2021;12:705512.","DOI":"10.3389\/fgene.2021.705512"},{"key":"2026062310301875000_2026.06.18.733244v1.47","doi-asserted-by":"crossref","unstructured":"Zhang Q , et al. Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization. J Immunother Cancer. 2022;10(10).","DOI":"10.1136\/jitc-2022-004666"},{"key":"2026062310301875000_2026.06.18.733244v1.48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2026062310301875000_2026.06.18.733244v1.49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"2026062310301875000_2026.06.18.733244v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2026062310301875000_2026.06.18.733244v1.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2026062310301875000_2026.06.18.733244v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30496-0"},{"key":"2026062310301875000_2026.06.18.733244v1.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01821-3"},{"key":"2026062310301875000_2026.06.18.733244v1.54","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"issue":"23","key":"2026062310301875000_2026.06.18.733244v1.55","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-25-0635","article-title":"Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas","volume":"31","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062310301875000_2026.06.18.733244v1.56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1471"},{"issue":"1","key":"2026062310301875000_2026.06.18.733244v1.57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-025-02173-y","article-title":"Disordered DNA methylation leads to targetable transcriptional plasticity in ATRT","volume":"14","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"2026062310301875000_2026.06.18.733244v1.58","doi-asserted-by":"crossref","unstructured":"Tetens AR , et al. DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically. Neurooncol Adv. 2024;6(1):vdae023.","DOI":"10.1093\/noajnl\/vdae023"},{"issue":"7","key":"2026062310301875000_2026.06.18.733244v1.59","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/2767-9764.CRC-23-0566","article-title":"Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma","volume":"4","year":"2024","journal-title":"Cancer Research Communications"},{"key":"2026062310301875000_2026.06.18.733244v1.60","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02628-x"},{"issue":"1","key":"2026062310301875000_2026.06.18.733244v1.61","doi-asserted-by":"crossref","first-page":"200766","DOI":"10.1016\/j.omton.2024.200766","article-title":"Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy","volume":"32","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"2026062310301875000_2026.06.18.733244v1.62","doi-asserted-by":"crossref","unstructured":"Talele C , et al. Cancer-testis antigens (CTAs) in lung cancer. Clin Chim Acta. 2026;579:120687.","DOI":"10.1016\/j.cca.2025.120687"},{"key":"2026062310301875000_2026.06.18.733244v1.63","doi-asserted-by":"crossref","unstructured":"Rossi A , et al. Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials. Int J Mol Sci. 2024;25(21).","DOI":"10.3390\/ijms252111740"},{"key":"2026062310301875000_2026.06.18.733244v1.64","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy050"},{"key":"2026062310301875000_2026.06.18.733244v1.65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0402-4"},{"issue":"1","key":"2026062310301875000_2026.06.18.733244v1.66","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","year":"2020","journal-title":"Scientific reports"},{"key":"2026062310301875000_2026.06.18.733244v1.67","doi-asserted-by":"crossref","unstructured":"Maes K , et al. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Front Immunol. 2021;12:652160.","DOI":"10.3389\/fimmu.2021.652160"},{"key":"2026062310301875000_2026.06.18.733244v1.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2054-x"},{"key":"2026062310301875000_2026.06.18.733244v1.69","doi-asserted-by":"publisher","DOI":"10.1038\/nm1602"},{"key":"2026062310301875000_2026.06.18.733244v1.70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0377"},{"key":"2026062310301875000_2026.06.18.733244v1.71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042167"},{"issue":"6","key":"2026062310301875000_2026.06.18.733244v1.72","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nprot.2007.202","article-title":"Extraction, purification and analysis of histones","volume":"2","year":"2007","journal-title":"Nature protocols"},{"key":"2026062310301875000_2026.06.18.733244v1.73","doi-asserted-by":"crossref","unstructured":"Gatla HR , et al. Cytokine Bioassays. Springer; 2014:271\u201383.","DOI":"10.1007\/978-1-4939-0928-5_25"},{"issue":"28","key":"2026062310301875000_2026.06.18.733244v1.74","doi-asserted-by":"crossref","first-page":"26347","DOI":"10.18632\/oncotarget.4713","article-title":"IKK inhibition increases bortezomib effectiveness in ovarian cancer","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"2026062310301875000_2026.06.18.733244v1.75","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.742247"},{"key":"2026062310301875000_2026.06.18.733244v1.76","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"2026062310301875000_2026.06.18.733244v1.77","doi-asserted-by":"crossref","unstructured":"Ktena YP , et al. Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. J Clin Invest. 2022;132(13).","DOI":"10.1172\/JCI158047"},{"key":"2026062310301875000_2026.06.18.733244v1.78","doi-asserted-by":"crossref","unstructured":"Koldobskiy MA , et al. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML. Epigenetics. 2020:1\u201318.","DOI":"10.1080\/15592294.2020.1734149"},{"key":"2026062310301875000_2026.06.18.733244v1.79","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2086-5"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.18.733244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:30:47Z","timestamp":1782235847000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.06.18.733244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":79,"URL":"https:\/\/doi.org\/10.64898\/2026.06.18.733244","relation":{},"subject":[],"published":{"date-parts":[[2026,6,21]]},"subtype":"preprint"}}